Syndax Pharmaceuticals announced that it plans to offer and sell, subject to market and other conditions, $150M of shares of its common stock in an underwritten public offering. Goldman Sachs & Co., J.P. Morgan, and Cowen are acting as joint book-running managers for the offering.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SNDX: